Patients with epidermal growth factor receptor (EGFR) positive non-small cell lung cancer (NSCLC) show improved response rates when treated with tyrosine kinase inhibitors (TKIs) such as erlotinib. However, standard daily dosing of erlotinib often does not reach therapeutic concentrations within the cerebrospinal fluid (CSF), resulting in progression of central nervous system (CNS) disease. Intermittent, high dose administration of erlotinib reaches therapeutic concentrations within the CSF and is well-tolerated in patients.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lq3g6Q
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Point of view: Electrophysiological endpoints differ when comparing the mode of action of highly successful... Point of view: Electrophysiol...
-
In view of the performance requirements (e.g., ride comfort, road holding, and suspension space limitation) for vehicle suspension systems, ...
-
Related Articles Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol:...
-
Abstract The core mission of the Early Stage Professionals in Molecular Imaging Sciences (ESPMIS) Interest Group is to help young scientist...
-
Abstract Background A reported penicillin allergy may compromise receipt of recommended antibiotic prophylaxis intended to prevent surgica...
-
Background Moyamoya angiopathy (MMA) is characterised by a progressive stenosis of the terminal part of the internal carotid arteries and th...
-
Ravikiran N Pawar, Sambhunath Banerjee, Subhajit Bramha, Shekhar Krishnan, Arpita Bhattacharya, Vaskar Saha, Anupam Chakrapani, Saurabh Bhav...
-
Objectives A major measure of treatment success for drug users undergoing rehabilitation is the ability to enter the workforce and generate ...
-
Context. Despite improvement in pain management and availability of clinical treatment guidelines, patients in Jordan are still suffering fr...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου